Novo says launch of obesity drug CagriSema in Europe delayed by a couple of years

Novo Nordisk announced it will not bring its obesity candidate CagriSema to European markets for the next few years.

The statement came from the company's outgoing chief financial officer, Karsten Munk Knudsen, during an interview with Endpoints News. He said the timeline for a European launch has been extended.

The postponement means European patients will have to wait longer for access, while the company may focus on other regions or further development of the product.